Compare NRG Energy Inc (NRG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NRG Energy Inc vs State Street SPDR S&P Biotech ETF — how do they compare? NRG Energy Inc trades at $107.73 (market cap $22.35B), while State Street SPDR S&P Biotech ETF trades at $153.62 (market cap $10.11B). The key difference: NRG Energy Inc is far larger — about 2.2× State Street SPDR S&P Biotech ETF's market cap, and NRG Energy Inc pays a 1.79% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold NRG Energy Inc for 63 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| NRG | XBI | |
|---|---|---|
Market Cap | $22.35B | $10.11B |
Volume | 5,011,942 | 12,903,266 |
Sector | Utilities | Broad Market / Factor |
52-Week High | $184.03 | $169.55 |
52-Week Low | $95.23 | $104.99 |
Typical Hold Time | 63 Days | 38 Days |
Enterprise Value | $46.30B | — |
Dividend Yield | 1.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRG Energy trades at $107.24, down 1.26% on the day, with a bullish technical signal supported by moving averages. The company shows strong profitability with 26.77% ROE and 2.56% net margin, though recent Q1 and Q2 2026 earnings missed expectations. Revenue growth remains positive, reaching $30.71B in 2025, while valuation metrics show a P/E of 27.69 and P/S of 0.65. Recent developments include a 1.2 GW Texas data center power project and potential acquisition of a West Virginia coal plant.
Outlook remains positive with analyst consensus strongly bullish (70% buy ratings) and a $202.90 price target suggesting significant upside. Key risks include rising debt levels (56.42% debt-to-asset ratio) and execution challenges on major capital projects. The company's dual retail/generation model provides stability, but investors should monitor earnings delivery against high expectations.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
